<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318356</url>
  </required_header>
  <id_info>
    <org_study_id>205520003-20110307</org_study_id>
    <secondary_id>2011-000643-25</secondary_id>
    <nct_id>NCT01318356</nct_id>
  </id_info>
  <brief_title>The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment</brief_title>
  <acronym>Qure</acronym>
  <official_title>The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy of two treatment strategies for fatigue&#xD;
      and disabilities in QFS: long term treatment with doxycycline or cognitive behavioral therapy&#xD;
      (CBT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Q fever fatigue syndrome (QFS) is one of the most frequent sequelae of Q fever, and&#xD;
      constitutes a significant problem in the current outbreak of Q fever. QFS leads to&#xD;
      substantial morbidity and has a high socio-economic burden, related to increased use of&#xD;
      healthcare facilities and absence from work. It is envisaged that over 750 patients will&#xD;
      become chronically fatigued due to Q fever in The Netherlands (20% of 4000 patients from 2007&#xD;
      until now). Although the outbreak appears to diminish, it is expected that Q fever will&#xD;
      remain an endemic disease, and therefore this number will continue to grow. A vast medical&#xD;
      consumption can be anticipated, stressing the need for an accessible and effective&#xD;
      intervention and clear treatment guidelines.&#xD;
&#xD;
      The study will contribute to a better understanding of effective treatment of QFS, providing&#xD;
      evidence-based guidelines for general practitioners and medical specialists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Checklist Individual Strength (CIS)</measure>
    <time_frame>24 weeks after start of treatment</time_frame>
    <description>The primary outcome measure is the fatigue severity measured by the subscale fatigue severity (8 items, 7-point Likert Scale) of the Checklist Individual Strength (CIS questionnaire) with a severity range from 8-56. High scores indicate a high level of fatigue. Patients with a cut-off score of ≥35 are classified as severely fatigued.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sickness Impact Profile (SIP) Total Score</measure>
    <time_frame>24 weeks after start of treatment</time_frame>
    <description>Level of functional impairment measured with the Sickness Impact Profile (SIP). The SIP is an instrument that is used to gauge sickness-related dysfunction. The weighted total score on eight subscales of the SIP8 (SIP8 total score) will be used to assess functional disability in all domains of functioning (range 0-5799). A higher score indicates higher levels of functional impairment. A score of 450 or higher on the SIP is defined as being significant disabled because of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist 90 (SCL90)</measure>
    <time_frame>24 weeks after start of treatment</time_frame>
    <description>The total score of the Symptom Checklist 90 (SCL90) measures the level of psychological distress. The SCL90 consists of 90 items scored on a 5-point scale. Scores range from 90 to 450. A low total score reflects high psychological well-being. The SCL-90 is a reliable and valid instrument.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Q Fever</condition>
  <condition>Fatigue Syndrome, Chronic</condition>
  <condition>Coxiella Infection</condition>
  <arm_group>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <description>CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
    <other_name>Behavior Therapy, Cognitive</other_name>
    <other_name>Cognition Therapy</other_name>
    <other_name>Cognitive Behavior Therapy</other_name>
    <other_name>Cognitive Psychotherapy</other_name>
    <other_name>Psychotherapy, Cognitive</other_name>
    <other_name>Therapy, Cognition</other_name>
    <other_name>Therapy, Cognitive</other_name>
    <other_name>Therapy, Cognitive Behavior</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Doxycycline Monohydrate</other_name>
    <other_name>Tetracycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sham Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant, non-lactating females who are 18 years or older&#xD;
&#xD;
          -  Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a&#xD;
             past infection with Coxiella burnetii;&#xD;
&#xD;
          -  AND being severely fatigued, defined by scoring 35 or higher on the subscale fatigue&#xD;
             severity of the CIS;&#xD;
&#xD;
          -  AND being fatigued for at least 6 months;&#xD;
&#xD;
          -  AND disabled because of the fatigue, defined by scoring 450 or higher on the SIP&#xD;
&#xD;
          -  Subjects must sign a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fulfilling criteria for chronic Q fever, namely:&#xD;
&#xD;
               -  IFA IgG fase I ≥ 1024, ≥ 3 months after acute Q fever and/or&#xD;
&#xD;
               -  Positive Coxiella burnetii PCR on serum or tissue, 1 month after acute Q fever&#xD;
&#xD;
          -  Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or&#xD;
             stenting necessitating prophylactic use of doxycycline;&#xD;
&#xD;
          -  Pregnancy or unwillingness to use effective contraceptives during the entire study&#xD;
             period;&#xD;
&#xD;
          -  Imminent death;&#xD;
&#xD;
          -  Inability to give informed consent;&#xD;
&#xD;
          -  Allergy or intolerance to doxycycline;&#xD;
&#xD;
          -  Somatic or psychiatric illness that could explain the chronic fatigue;&#xD;
&#xD;
          -  Subjects who are currently enrolled on other investigational drug trials or receiving&#xD;
             investigational agents;&#xD;
&#xD;
          -  Receiving antibiotics for more than 4 weeks, potentially active against Coxiella&#xD;
             burnetii, for any other reason since Q-fever diagnosis;&#xD;
&#xD;
          -  Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or&#xD;
             carbamazepine (these drugs may increase the metabolism of doxycycline and therefore&#xD;
             reducing half-life of doxycycline);&#xD;
&#xD;
          -  Moderate or severe liver disease (AF, ALAT, ASAT &gt; 3 times the upper limit of normal).&#xD;
&#xD;
          -  Current engagement in a legal procedure concerning financial benefits (only current&#xD;
             involvement interferes with the effectivity of cognitive behavioral therapy. Once the&#xD;
             appeal procedure ends, subjects can be included)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal P Bleeker-Rovers, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Keijmel SP, Delsing CE, Sprong T, Bleijenberg G, van der Meer JW, Knoop H, Bleeker-Rovers CP. The Qure study: Q fever fatigue syndrome--response to treatment; a randomized placebo-controlled trial. BMC Infect Dis. 2013 Mar 27;13:157. doi: 10.1186/1471-2334-13-157.</citation>
    <PMID>23536997</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <results_first_submitted>March 9, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Stephan Keijmel</investigator_full_name>
    <investigator_title>S.P. Keijmel, MD</investigator_title>
  </responsible_party>
  <keyword>Q fever</keyword>
  <keyword>Cognitive behavioral therapy</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Coxiella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Q Fever</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>156 patients signed informed consent and were randomized; of these, 155 started treatment, either doxycycline (n = 52), placebo (n = 52), or CBT (n = 51). One patient refused double-blind randomization after allocation to the medication group, and received no treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline</title>
          <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline</title>
          <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="13.7"/>
                    <measurement group_id="B2" value="43.6" spread="10.2"/>
                    <measurement group_id="B3" value="44.6" spread="12.3"/>
                    <measurement group_id="B4" value="43.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sickness Impact Profile 8 total score</title>
          <description>The SIP is an instrument that is used to gauge sickness-related dysfunction. The weighted total score on eight subscales of the SIP8 (SIP8 total score) will be used to assess functional disability in all domains of functioning. Values range from 0-4999. Higher scores reflect a higher level of functional impairment.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1369.4" spread="646.7"/>
                    <measurement group_id="B2" value="1304.9" spread="537.7"/>
                    <measurement group_id="B3" value="1295.1" spread="593.7"/>
                    <measurement group_id="B4" value="1322.8" spread="591.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Checklist Individual Strength, subscale fatigue</title>
          <description>The primary outcome measure is the fatigue severity measured by the subscale fatigue severity (8 items, 7-point Likert Scale) of the Checklist Individual Strength (CIS questionnaire) with a severity range from 8-56. High scores indicate a high level of fatigue. Patients with a cut-off score of ≥35 are classified as severely fatigued.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="4.7"/>
                    <measurement group_id="B2" value="51.4" spread="4.7"/>
                    <measurement group_id="B3" value="50.2" spread="4.8"/>
                    <measurement group_id="B4" value="50.36" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom Checklist 90 total score</title>
          <description>Level of psychological distress measured with the total score of the Symptom Checklist 90 (SCL90). The SCL90 consist of 90 items scored on a fivepoint scale. Scores range from 90-450. A low total score reflects psychological well-being.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.4" spread="35.0"/>
                    <measurement group_id="B2" value="152.2" spread="31.4"/>
                    <measurement group_id="B3" value="159.1" spread="41.0"/>
                    <measurement group_id="B4" value="155.6" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of symptoms</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="22" upper_limit="59"/>
                    <measurement group_id="B2" value="36" lower_limit="24.25" upper_limit="57"/>
                    <measurement group_id="B3" value="37.50" lower_limit="25.50" upper_limit="50.75"/>
                    <measurement group_id="B4" value="39" lower_limit="24" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Checklist Individual Strength (CIS)</title>
        <description>The primary outcome measure is the fatigue severity measured by the subscale fatigue severity (8 items, 7-point Likert Scale) of the Checklist Individual Strength (CIS questionnaire) with a severity range from 8-56. High scores indicate a high level of fatigue. Patients with a cut-off score of ≥35 are classified as severely fatigued.</description>
        <time_frame>24 weeks after start of treatment</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Checklist Individual Strength (CIS)</title>
          <description>The primary outcome measure is the fatigue severity measured by the subscale fatigue severity (8 items, 7-point Likert Scale) of the Checklist Individual Strength (CIS questionnaire) with a severity range from 8-56. High scores indicate a high level of fatigue. Patients with a cut-off score of ≥35 are classified as severely fatigued.</description>
          <population>Intention-to-treat analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="28.0" upper_limit="35.1"/>
                    <measurement group_id="O2" value="40.8" lower_limit="37.3" upper_limit="44.3"/>
                    <measurement group_id="O3" value="37.8" lower_limit="34.3" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sickness Impact Profile (SIP) Total Score</title>
        <description>Level of functional impairment measured with the Sickness Impact Profile (SIP). The SIP is an instrument that is used to gauge sickness-related dysfunction. The weighted total score on eight subscales of the SIP8 (SIP8 total score) will be used to assess functional disability in all domains of functioning (range 0-5799). A higher score indicates higher levels of functional impairment. A score of 450 or higher on the SIP is defined as being significant disabled because of fatigue.</description>
        <time_frame>24 weeks after start of treatment</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Sickness Impact Profile (SIP) Total Score</title>
          <description>Level of functional impairment measured with the Sickness Impact Profile (SIP). The SIP is an instrument that is used to gauge sickness-related dysfunction. The weighted total score on eight subscales of the SIP8 (SIP8 total score) will be used to assess functional disability in all domains of functioning (range 0-5799). A higher score indicates higher levels of functional impairment. A score of 450 or higher on the SIP is defined as being significant disabled because of fatigue.</description>
          <population>Intention-to-treat analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="786.8" lower_limit="615.3" upper_limit="958.3"/>
                    <measurement group_id="O2" value="1101.5" lower_limit="933.5" upper_limit="1269.6"/>
                    <measurement group_id="O3" value="963.8" lower_limit="795.8" upper_limit="1131.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Checklist 90 (SCL90)</title>
        <description>The total score of the Symptom Checklist 90 (SCL90) measures the level of psychological distress. The SCL90 consists of 90 items scored on a 5-point scale. Scores range from 90 to 450. A low total score reflects high psychological well-being. The SCL-90 is a reliable and valid instrument.</description>
        <time_frame>24 weeks after start of treatment</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Checklist 90 (SCL90)</title>
          <description>The total score of the Symptom Checklist 90 (SCL90) measures the level of psychological distress. The SCL90 consists of 90 items scored on a 5-point scale. Scores range from 90 to 450. A low total score reflects high psychological well-being. The SCL-90 is a reliable and valid instrument.</description>
          <population>Intention-to-treat analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.1" lower_limit="119.4" upper_limit="134.7"/>
                    <measurement group_id="O2" value="149.2" lower_limit="141.6" upper_limit="156.7"/>
                    <measurement group_id="O3" value="142.6" lower_limit="134.1" upper_limit="150.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety was assessed by monitoring adverse events (AEs) and concomitant drug use. For patients allocated to the medication condition, AEs were monitored at 4 weeks, 8 weeks, and 16 weeks after start of therapy, and at EOT (= up to approximately 26 weeks after start of therapy). Furthormore, if applicable, during the trial when reported by the patient. For patients allocated to CBT, AEs were monitored at 8 weeks after start of therapy, and at EOT (up to 26 weeks after start of therapy).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive behavioral therapy: CBT will consist of a protocolized intervention during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline</title>
          <description>Doxycycline: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiological symptoms</sub_title>
                <description>The other patient was admitted for clinical evaluation of preexisting cardiological symptoms, which yielded no diagnosis.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>One patient who had not yet started treatment was admitted to hospital with urosepsis.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastointestinal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="51" subjects_affected="31" subjects_at_risk="52"/>
                <counts group_id="E3" events="33" subjects_affected="27" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" events="34" subjects_affected="24" subjects_at_risk="52"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="54" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E3" events="46" subjects_affected="26" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laboratorial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bone and teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="29" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was not designed to compare doxycycline and CBT directly, due to the limited number of available patients.&#xD;
As masking for CBT was not possible, this trial was partly blinded. CBT was directly compared to placebo plus usual care.&#xD;
Due to the maximum number of vailable patients, it was not possible to include a control group without any form of treatment.&#xD;
Finally, it is unclear whether the detected effects will be sustained over time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>S.P. Keijmel, MD PhD</name_or_title>
      <organization>Radboud university medical center</organization>
      <phone>0031243611111</phone>
      <email>stephan.keijmel@radboudumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

